Globus Medical, Inc.
GMEDHealthcareNASDAQMedical Devices · Last scanned Oct 26, 2026
Scan Results
Daily timeframeGlobus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. Valued at $10.93B, GMED is a large-cap name in its sector. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives.
Market Cap
$10.93B
Beta
0.96
P/E (TTM)
20.87
P/E (Fwd)
15.10
EPS (TTM)
$3.90
EPS (Fwd)
$5.39
ROE
11.8%
ROA
8.7%
Cash
$595.1M
Total Debt
$111.9M
Free CF
$554.2M
52W Change
28.7%
Annual Financials
Cash vs Debt
Where GMED stands vs its 150-day and 200-day moving averages
As of the September 30, 2026 close, GMED finished 8.95% below its 150-day moving average ($83.13) and 10.76% below its 200-day moving average ($84.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GMED overbought or oversold?
At the September 30, 2026 close, GMED's RSI(14) was 55.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $595.1M in cash and $111.9M in debt, GMED maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company generates $554.2M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 11.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.02B (2022) to $2.94B (2025), reflecting a 187% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Globus Medical, Inc.'s trajectory.